Logo-bi
Editorial
Mostafa Akbarzadeh Khiavi ORCID, Azam Safary ORCID, Mohammad Hossein Somi* ORCID
Bioimpacts. 2019;9(3): 123-127. doi: 10.15171/bi.2019.16
PMCID: PMC6726747     PMID: 31508327     Scopus ID: 85071152476    
Colorectal cancer (CRC) as a malignancy shows high mortality rate worldwide because of metastasis and drug resistance. Targeted multimodal nanosystems (NSs) can be developed and used against CRC with much better clinical outcomes.
Original Research
Mostafa Akbarzadeh Khiavi ORCID, Azam Safary ORCID, Jaleh Barar ORCID, Hamed Farzi-Khajeh, Abolfazl Barzegari, Rahimeh Mousavi, Mohammad Hossein Somi* ORCID, Yadollah Omidi* ORCID
Bioimpacts. 2020;10(1): 27-36. doi: 10.15171/bi.2020.04
PMCID: PMC6977588     PMID: 31988854     Scopus ID: 85078959970    
The current study introduces an efficient ROS-responsive enzyme-based nanobiosystem and its biological impact in colon cancer therapy. Based on physicochemical properties, AuNPs-PEG-RNase A effectively induced apoptosis in SW-480 colon cancer cells and resulted in a significant reduction in cancer cell viability.
Original Research
Roya Dolatkhah ORCID, Saeed Dastgiri ORCID, Amir Taher Eftekhar Sadat, Faris Farassati, Marzieh Nezamdoust, Mohammad Hossein Somi* ORCID
BioImpacts. 2021;11(1): 5-14. doi: 10.34172/bi.2021.02
PMCID: PMC7803924     PMID: 33469503     Scopus ID: 85099264583    
It has been suggested that the pattern of specific mutation including KRAS/NRAS/BRAF, are associated with different prognostic values and responses to anti-EGFR therapies.
Original Research
Nurul Azmir Amir Hashim ORCID, Sharaniza Ab-Rahim, Wan Zurinah Wan Ngah, Sheila Nathan, Nurul Syakima Ab Mutalib, Ismail Sagap, A. Rahman A. Jamal, Musalmah Mazlan* ORCID
BioImpacts. 2021;11(1): 33-43. doi: 10.34172/bi.2021.05
PMCID: PMC7803921     PMID: 33469506     Scopus ID: 85099260140    
Global Serum from metabolomics on colorectal cancer (CRC) identified 11 differential metabolites which able to identify a new set of sample with 80% of accuracy. Pathway analysis shows purine, catecholamine and amino acid metabolism were altered in CRC patients.
Original Research
Hazwani Mohd Yusof ORCID, Sharaniza Ab-Rahim, Wan Zurinah Wan Ngah, Sheila Nathan, A Rahman A Jamal, Musalmah Mazlan* ORCID
BioImpacts. 2021;11(2): 147-156. doi: 10.34172/bi.2021.22
PMCID: PMC8022234     PMID: 33842285     Scopus ID: 85106574295    
This study highlights the differential metabolite profiling in CRC cell lines corresponding to different stages.
Original Research
Ainaz Mihanfar, Bahman Yousefi, Saber Ghazizadeh Darband, Shirin Sadighparvar, Mojtaba Kaviani, Maryam Majidinia* ORCID
BioImpacts. 2021;11(4): 253-261. doi: 10.34172/bi.2021.36
PMCID: PMC8494259     PMID: 34631487     Scopus ID: 85113774001    
Treatment of SW-480 cancer cell lines with a combination of 5-FU and melatonin results in the increment in the sensitivity of cancer cells to 5-FU through downregulation of XIAP and survivin, as well as modulation of oxidative stress.
Original Article
Samaneh Tokhanbigli ORCID, Helia Alavifard ORCID, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali, Kaveh Baghaei* ORCID
Bioimpacts. 2023;13(4): 333-346. doi: 10.34172/bi.2022.24209
PMCID: PMC10460770     PMID: 37645031     Scopus ID: 85154024997    
Combining LY6E loaded DC therapy with pioglitazone improved the DC therapy effect for colorectal cancer treatment. LY6E pulsed DCs excites the CD8 positive immune responses against colorectal models. Pioglitazone inhibits IL-6 axis and formation of CRC cell lines proliferation through IL-6/STAT3 by influencing the immunosuppressive feature of the tumor microenvironment.
Editorial
Mostafa Akbarzadeh-Khiavi ORCID, Azam Safary ORCID, Yadollah Omidi* ORCID
Bioimpacts. 2024;14(1): 27696. doi: 10.34172/bi.2023.27696
PMCID: PMC10844586     PMID: 38327631    
PDF
XML
Cited By: